Status:
COMPLETED
Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
Lead Sponsor:
Merrion Pharmaceuticals, LLC
Conditions:
Hormone-Refractory Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
The objective of MER-101-03 is to examine the effects of two different dosing regimens of MER-101 20mg tablets versus Zometa 4mg IV infusion once-monthly therapy. The effects will be monitored on a we...
Eligibility Criteria
Inclusion
- Prostate Cancer with rising PSA levels after hormone treatment and bone metastasis based on an X-ray.
Exclusion
- Already be on a bisphosphonate treatment (Zometa, Fosamax, Actonel)
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00636740
Start Date
February 1 2008
End Date
February 1 2009
Last Update
February 20 2009
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham Hematology & Oncology Associates, LLC
Birmingham, Alabama, United States, 35223
2
Cancer Care of North Florida, P.A.
Lake City, Florida, United States, 32055
3
Lakeland Regional Cancer Center
Lakeland, Florida, United States, 33805
4
Innovative Medical Research of South Florida, Inc.
Miami, Florida, United States, 33179